AbbVie | ABBV - Operating Expenses


AbbVie reported $10.27B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Abbott USD 9.31B 104M Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eisai JPY 215.74B 15.84B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
J&J USD 17.44B 1.53B Mar/2026
Medtronic USD 7.72B 436M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
UCB EUR 2.96B 196M Dec/2025
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Zoetis USD 3.23B 1.68B Mar/2026